Borgen E, Beiske K, Trachsel S, Nesland J M, Kvalheim G, Herstad T K, Schlichting E, Qvist H, Naume B
Department of Pathology, Norwegian Radium Hospital, University of Oslo, Norway.
J Pathol. 1998 Aug;185(4):427-34. doi: 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7.
Detection of isolated tumour cells (TCs) in bone marrow (BM) from epithelial cancer patients by immunocytochemical (ICC) analysis seems to predict future relapse, but the reported percentages of positive BMs among patients with localized cancer show large variations and the number of detected TCs is low. This emphasizes the importance of thoroughly testing the methods in use. This study was performed to clarify to what extent positive staining of haematopoietic cells (HCs) interferes with the ICC detection of epithelial cells in BM. BM mononuclear cells (MNCs) from normal donors and stage I-II breast cancer patients were stained with anti-cytokeratin (CK) and isotype control monoclonal antibodies (MAbs) followed by alkaline phosphatase (AP)-based visualization of immunolabelled cells. In the ICC staining of normal donors by the anti-CK MAbs AE1/AE3 or A45-B/B3, rare immunoreactive cells were detected in 7/20 and 8/19 BMs, respectively. Morphological examination recognized all these cells as typical HCs. In the breast cancer patients (n = 257), anti-CK-positive cells were detected in 26.6 per cent, excluding cells with HC morphology. Using the same morphological criteria, isotype control-positive cells were detected in 5.4 per cent of patients. Some of the false-positive events were further analysed and cells with strong reactivity against the AP enzyme alone were detected. Double ICC staining recognized the majority of these AP directly-reactive cells as CD45-negative and human Ig kappa/lambda-positive, in accordance with the phenotype of mature plasma cells. Morphological evaluation and adequate controls are important to ensure the diagnostic specificity of micrometastases in BM. It is recommended that the number of BM MNCs included in negative controls should equal the number of cells in the diagnostic specimens.
通过免疫细胞化学(ICC)分析检测上皮癌患者骨髓(BM)中的孤立肿瘤细胞(TCs)似乎可以预测未来复发,但局部癌症患者中报告的阳性骨髓百分比差异很大,且检测到的TCs数量很少。这凸显了全面测试所用方法的重要性。本研究旨在阐明造血细胞(HCs)的阳性染色在多大程度上干扰了BM中上皮细胞的ICC检测。来自正常供体和I-II期乳腺癌患者的BM单核细胞(MNCs)用抗细胞角蛋白(CK)和同型对照单克隆抗体(MAbs)染色,随后基于碱性磷酸酶(AP)对免疫标记细胞进行可视化。在抗CK单克隆抗体AE1/AE3或A45-B/B3对正常供体的ICC染色中,分别在7/20和8/19例骨髓中检测到罕见的免疫反应性细胞。形态学检查将所有这些细胞识别为典型的HCs。在乳腺癌患者(n = 257)中,排除具有HC形态的细胞后,检测到26.6%的抗CK阳性细胞。使用相同的形态学标准,在5.4%的患者中检测到同型对照阳性细胞。对一些假阳性事件进行了进一步分析,检测到仅对AP酶有强反应性的细胞。双重ICC染色根据成熟浆细胞的表型将这些直接对AP有反应的细胞中的大多数识别为CD45阴性和人Ig κ/λ阳性。形态学评估和适当的对照对于确保BM中微转移的诊断特异性很重要。建议阴性对照中包含的BM MNCs数量应与诊断标本中的细胞数量相等。